返回 
加入收藏
新政策环境下创新药物临床试验风险识别及评估
x
请在关注微信后，向客服人员索取文件
| 篇名： | 新政策环境下创新药物临床试验风险识别及评估 |
| TITLE： | Risk Identification and Evaluation of Clinical Trials of I nnovative Drugs under New Policy Environment |
| 摘要： | 目的：识别并评估创新药物临床试验的风险因素，为制定其风险管控策略提供参考。方法：运用文献研究法，获取创新药物临床试验阶段的风险因素，进行分类整理，初步形成风险评价指标，并在此基础上设计调查问卷；通过采用面谈访问、问卷调查等方式，邀请4家三甲医院及1家合同研究组织的54位专家进行评分；运用SPSS24.0软件对风险事件状态数据进行主成分分析。结果与结论：形成的风险评估体系包括政策法律风险、临床试验机构风险、试验方案设计风险等9项一级指标，行业政策和法律法规变化、知识产权风险等31项二级指标。经分析，创新药物临床试验风险因素主要为药品及生物样本管理风险、试验方案设计风险、临床试验机构风险、安全性报告管理风险、伦理审查风险、政策法律风险和受试者管理风险等。临床试验相关方需要重点监测各风险因素，建立动态化的监控管控机制和实施保障机制，有效预防和管控风险，促进临床试验顺利实施。 |
| ABSTRACT： | OBJECTIVE：To identify and evaluate the risk factors of innovative drug clinical trials ，and to provide references for the development of risk management and control strategies. METHODS ：Using the method of literature research ，the risk factors of innovative drug clinical trials were obtained ，classified and sorted out ，and the risk evaluation indicators were initially formed. On this basis ，the questionnaire was designed. By means of interview and questionnaire survey ，54 experts were invited from 4 tertiary hospitals and 1 contract research organization to score. SPSS 24.0 software was used to perform principal component analysis on risk event status data. RESULTS & CONCLUSIONS ：The risk evaluation system included 9 first-class indicators such as policy and legal risk ，clinical trial institution risk and trial scheme design risk ，and 31 second-class indicators such as industrial policy，law and regulation changes ，intellectual property risk . According to the analysis ，the risk factors of innovative drug clinical trials mainly included drug and biological sample management risk ，trial scheme design risk ，clinical trial institution risk ，safety report management risk ，ethical review risk ，policy and legal risk ，and subject management risk. Relevant parties in clinical trials need to focus on monitoring various risk factors ，establish dynamic monitoring and control mechanism and implementation guarantee mechanism ，and effectively prevent and control risk ，to promote the smooth implementation of clinical trials. |
| 期刊： | 2021年第32卷第10期 |
| 作者： | 安晓玲，黄文强，苏雨楠，罗臻 |
| AUTHORS： | AN Xiaoling ，HUANG Wenqiang ，SU Yunan ，LUO Zhen |
| 关键字： | 创新药物临床试验；新政策环境；主成分分析法；风险识别；风险评估 |
| KEYWORDS： | Clinical trials of innovative drugs ；New policy environment ；Principal component analysis ；Risk identification ； |
| 阅读数： | 400 次 |
| 本月下载数： | 21 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
